31 results about "Renal filtrate" patented technology

Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and / or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.

This utility model relates to the field of urine collection bag technology and discloses a urine collection bag for bladder irrigation in urological patients. It includes a lifting arm and a urine collection bag. A hook is fixedly connected to the middle of the upper surface of the lifting arm, and a warning light is installed in the middle of one side of the lifting arm. A power supply is installed inside the lifting arm. Slides are formed on both sides of the lifting arm. A conductive block is fixedly connected to one side of the bottom wall of the slide, and a spring is fixedly connected to the other side of the bottom wall of the slide. An inlet pipe is fixedly connected to one side of the upper surface of the urine collection bag, and a drain pipe is fixedly connected to the middle of the lower surface of the urine collection bag. This urine collection bag for bladder irrigation, through the design of an observation window and built-in scale lines, reduces the interference of bag deformation and light refraction on readings. Nursing staff can intuitively and accurately read the volume of irrigation waste fluid, ensuring accurate recording of intake and output balance, and providing reliable data support for assessing the patient's bladder irrigation effect, bleeding, and renal function recovery.

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

This invention belongs to the field of traditional Chinese medicine treatment of acute kidney injury, and provides a traditional Chinese medicine composition for treating sepsis-related acute kidney injury and its preparation method. It is prepared by mixing honeysuckle, forsythia, roasted peach kernel, raw rhubarb, raw astragalus, wine-processed angelica, cinnamon twig, mirabilite, and raw licorice in a certain proportion. It detoxifies and removes blood stasis, invigorates qi and unblocks the meridians. It is used for persistent high fever and difficulty in urination and defecation caused by internal accumulation of toxic heat and blood stasis. Symptoms include oliguria or dribbling, red tongue, and rapid pulse; it is also used for sepsis patients with the above symptoms. Treatment with the detoxifying and blood-stasis-removing granules improved survival rate, effectively restored some renal function, reduced renal tubular damage, and decreased TNF-α and IL-1β expression. Immunohistochemical and Western blot results were consistent. The detoxifying and blood-stasis-removing granules can alleviate sepsis-induced acute kidney injury.

This invention provides a traditional Chinese medicine composition for treating renal edema, pyelonephritis with ascites, and nephritis. It consists of over 20 herbs including Atractylodes lancea, Areca catechu, Saposhnikovia divaricata, and Alisma plantago-aquatica (specific formulation details can be found in the original text). It can be prepared as pills, granules, or decoctions for oral administration. Core efficacy: 1. Promotes diuresis and reduces swelling, eliminating renal ascites; 2. Clears heat and detoxifies, anti-inflammatory and antibacterial (synergistic effect on fungal infections and cervical erosion); 3. Regulates renal function and improves abnormal uric acid metabolism. Treatment plan: Mild cases: Use five basic formulas (①-⑤) composed of Codonopsis pilosula, Poria cocos, etc., taken three times daily; Severe cases: Use a potent diuretic formula containing Akebia trifoliata and Euphorbia pekinensis (one spoonful of pills twice daily); Treatment course is approximately one month, with a follow-up examination after three months. Advantages: Cure rate reaches 90%, low recurrence rate – pure traditional Chinese medicine preparation, no significant toxic side effects; also treats complications (fungal infection, cervical lesions). This treatment plan has been clinically verified through three generations and has significant efficacy in treating renal edema, ascites, and nephritis.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

This invention belongs to the field of biomedical technology, specifically disclosing the use of neuron-derived neurotrophic factors in the preparation of drugs for the prevention and treatment of kidney stones. Using a glyoxylate-induced mouse model of kidney calcium deposition, this invention demonstrates that neuron-derived neurotrophic factors can significantly reduce kidney calcium deposition, alleviate renal tubular structural damage, and improve renal function indicators. This achieves comprehensive intervention in the entire process of kidney stone disease, from crystal formation to tissue damage to functional abnormalities, exhibiting superior technical effects compared to single stone-dissolving or stone-expelling strategies, and possesses significant application value and clinical translational potential.

The present invention provides non-human animals expressing human CFB protein or chimeric (e.g., humanized) CFB protein and methods for using the same. The present invention further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals containing the non-human animal genome and the humanized CFB gene. The non-human animals obtained in this application successfully express human CFB protein or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert similar effects in the human body. Furthermore, the non-human animals obtained in this application have complete renal function, normal blood biochemical indicators, and, more remarkably, do not exhibit the potential diseases observed in other transgenic mice known in this art.

Described herein are methods for treating and / or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

This invention discloses the use of LAPTM5 in the preparation of drugs regulating renal tubular epithelial-mesenchymal transition (EMT). Through bioinformatics analysis and multi-level experimental verification, this invention found that LAPTM5 is significantly upregulated in an aging kidney model and is positively correlated with renal aging and the severity of fibrosis. Mechanistic studies show that LAPTM5 interacts with the deubiquitinating enzyme USP10 and promotes its lysosomal degradation, weakening the deubiquitination effect of USP10 on PTEN. This leads to proteasomal degradation of PTEN via the K48-linked polyubiquitination pathway, thereby relieving PTEN's inhibition of the PI3K / AKT / mTOR signaling pathway, inhibiting autophagy activity, promoting renal tubular epithelial-mesenchymal transition, and accelerating the process of renal fibrosis. At the cellular level, PTEN overexpression can rescue LAPTM5-induced EMT; in animal models, the PTEN agonist matrine significantly improves D-galactose-induced renal fibrosis in aging mice and protects renal function by restoring autophagy.

The invention relates to the technical field of disease risk intelligent prediction, in particular to a chronic kidney disease progress risk prediction system based on machine learning, which comprises an accumulated impact acquisition module used for inputting disease information and physiological index data of a current patient into a disease risk transmission network to acquire an accumulated impact condition; the predicted eGFR calculation module is used for inputting the accumulated impact condition into an eGFR prediction regression network to obtain a predicted eGFR curve; the similarity analysis module is used for calculating a similarity measurement value between the eGFR curves of the current patient and each target historical patient; the risk value calculation module is used for obtaining a renal function attenuation risk value based on the predicted eGFR curve, the similarity measurement value and the eGFR difference value between the current patient and each target historical patient; and the risk judgment module is used for judging whether the current patient has a renal function collapse risk based on the renal function attenuation risk value. According to the invention, early and accurate prediction can be carried out on the CKD progress risk.

This invention discloses the application of *Bifidobacterium animalis* subsp. *lactamase* GOLDGUT-BB21 in lowering uric acid, belonging to the field of biomedical technology. This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 29347, on December 18, 2023, and is taxonomically named *Bifidobacterium animalis* subsp. *lactamase*. Bifidobacterium animalis subsp.lactis The present invention, Bifidobacterium lactis subspecies GOLDGUT-BB21, exhibits outstanding effects in lowering uric acid, improving renal function, regulating intestinal flora, and enhancing the intestinal barrier. It is safe, mild, and has multi-target synergistic characteristics, and can provide a highly efficient and promising microecological solution for nutritional intervention in hyperuricemia and related metabolic abnormalities.

The application of diosgenin in the preparation of drugs for the prevention or treatment of acute kidney injury falls within the pharmaceutical field. Specifically, this invention discloses that diosgenin, by directly binding to the PIK3CA protein, regulates the PI3K / Akt-NF-κB pathway, inhibiting inflammatory responses, apoptosis, and pyroptosis in renal tubular epithelial cells, thereby alleviating kidney damage. Cellular experiments show that diosgenin at concentrations of 0.1–5 μM can significantly protect renal tubular epithelial cells; animal experiments show that doses of 1–20 mg / kg can significantly improve renal function and reduce pathological damage in mice with acute kidney injury. This invention clarifies a complete chain of evidence from "compound—target—pathway—efficacy," providing a new drug candidate for the treatment of acute kidney injury and offering a paradigm for the mechanistic study of active ingredients in traditional Chinese medicine, contributing to the transformation of traditional Chinese medicine from empirical medicine to evidence-based and molecular medicine.

This invention discloses the application of a pharmaceutical composition containing curculigoside in the treatment of type 2 diabetic nephropathy, belonging to the technical field of diabetic nephropathy drugs. The pharmaceutical composition uses curculigoside and astragaloside A as active ingredients, and also includes pharmaceutically acceptable excipients, wherein the mass ratio of curculigoside to astragaloside A is 1:0.2 to 1:1.5. This invention is the first to apply curculigoside to the treatment of type 2 diabetic nephropathy. Through the synergistic effect of curculigoside and astragaloside A, it can significantly improve renal function in patients with type 2 diabetic nephropathy, inhibit inflammatory responses and oxidative stress, reduce renal pathological damage, and delay the progression of renal fibrosis. Furthermore, the pharmaceutical composition has high safety, no obvious adverse reactions, diverse dosage forms, and high medication adherence, overcoming the shortcomings of existing therapeutic drugs with limited efficacy and numerous adverse reactions, and has significant clinical value and broad application prospects.

This invention discloses the application of ZAK inhibitors in the preparation of drugs for treating EV71 virus infection, relating to the biomedical field. The ZAK inhibitors exert their effects by inhibiting the ZAK-p38 MAPK signaling pathway and by inhibiting the ZAKα-mediated ribosomal toxicity stress response (RSR). The ZAK inhibitor is nilotinib or a pharmaceutically acceptable salt thereof. Cellular and animal experiments of this invention demonstrate that EV71 infection activates the ZAKα-mediated p38 MAPK pathway (RSR), promoting viral replication and leading to multi-organ damage. ZAK inhibitors (such as nilotinib) can inhibit this pathway, reduce the expression of the viral protein VP1, and improve infection-induced renal function damage, metabolic disorders, and muscle damage. Therefore, ZAK inhibitors can be used to prepare anti-EV71 drugs.

This invention relates to the field of biomedical technology. Currently, there is no existing technology for the use of urolithin D in the treatment of acute kidney injury. This invention is the first to propose the application of urolithin D in the preparation of drugs for inhibiting and / or preventing and / or alleviating and / or treating acute kidney injury. Urolithin D is used to downregulate the expression of the kidney injury molecule KIM-1 and reduce the expression of F4 / 80 in macrophages. This invention also proposes a pharmaceutical formulation for inhibiting and / or preventing and / or alleviating and / or treating acute kidney injury, the formulation comprising an active ingredient and a pharmaceutically acceptable carrier. The active ingredient includes urolithin D. The pharmaceutical formulation is in the form of capsules, granules, oral liquid, or tablets. This invention reveals that in two authoritative AKI animal models (CLP and IRI), urolithin D can dose-dependently improve core renal function indicators (SCr, BUN) and renal pathological damage.

This invention relates to the field of medical and health information processing technology, specifically disclosing an early risk stratification and warning system and method for diabetic nephropathy. The system includes a data fusion preprocessing module, a multi-scale causal network construction module, a dynamic risk trajectory calculation module, and a stratified warning decision-making module, connected sequentially. By fusing multimodal data to construct an interpretable causal network and utilizing a network-constrained prediction model, it achieves dynamic trajectory prediction of future renal function indicators and comprehensive risk indices. Based on the prediction results, it triggers different levels of risk warnings and outputs decision support information, thereby achieving early, dynamic, and causally interpretable risk stratification and warning.

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.

This invention relates to a traditional Chinese medicine extract, its preparation method, and its uses. The extract is obtained by water extraction of raw materials composed of *Citrus aurantium* and *Rheum palmatum*, followed by extraction with ethyl acetate and n-butanol, respectively. The ethyl acetate extract and n-butanol extract can inhibit mesangial cell proliferation and improve renal function, and can be used to prepare drugs for treating mesangial proliferative glomerulonephritis.

This application provides a method and related equipment for predicting rapid renal function decline based on deep learning, belonging to the field of data processing technology. The method includes: acquiring the patient's preoperative original CT images and preoperative clinical characteristics; inputting the preoperative original CT images into an automatic segmentation network to extract the contralateral renal parenchymal region, obtaining the image features of the contralateral renal parenchymal region; constructing a multimodal rapid renal function decline prediction model based on a multi-head attention mechanism, fusing image features and preoperative clinical characteristics, to predict the patient's risk of rapid postoperative renal function decline; and outputting the prediction result of the risk of rapid postoperative renal function decline. This application can provide auxiliary decision support for the selection of surgical methods for patients with complex renal cell carcinoma before surgery, thereby reducing the risk of postoperative renal function damage, and has significant clinical application value.

This invention relates to the field of dialysis complication monitoring technology, specifically to a method for real-time monitoring and early warning of peritoneal dialysis complications in children. Based on the fluctuation of analytical data for each type of patient and the degree of difference between each monitoring and previous monitoring data, the method adjusts the degree of change in the turbidity value of the dialysis solution for each dialysis session, obtaining the turbidity variability of each analytical data point for each type of patient in each monitoring session. Based on the differences in turbidity variability of the same biochemical indicators between the patient and a control patient at different sampling times, and the differences in turbidity variability of the flow rate sequence at different dialysis sessions, the method obtains biochemical variability and flow rate variability, and adjusts these using the differences in renal function between the patient and the control patient. Based on a determined risk level, the method monitors and provides early warning for complications in the current dialysis session. This invention considers both individual differences and behavioral specificities, effectively reducing misdiagnosis of peritoneal dialysis complications.

This invention relates to the field of microbial technology, and in particular to a short-fermenting Lactobacillus strain capable of significantly preventing the progression of kidney disease and stabilizing renal function, and its uses. The strain of this invention has shown good efficacy in various kidney disease models, especially in a cisplatin-induced CKD model, significantly alleviating weight loss induced by platinum-based drugs in mice; it also provides excellent protection against platinum-based drug-induced intestinal inflammation and intestinal wall integrity; in the long term, it significantly alleviates platinum-based drug nephrotoxicity; it has a good stabilizing effect on renal function and can effectively prevent the progression of CKD. Therefore, the described strain can be used to prepare pharmaceutical compositions for stabilizing and improving renal function in acute and chronic kidney diseases, and can also be used to prepare drugs that reduce drug side effects, showing very broad application prospects.

This invention belongs to the field of biomedical technology and relates to the application of IIA compounds in the preparation of drugs for the treatment of kidney injury-related diseases. Through cell experiments and animal experiments, it has been confirmed that IIA-12 can reduce apoptosis levels, regulate immune inflammatory responses, and improve renal function in in vivo and in vitro models of ischemia-reperfusion kidney injury. IIA-12 can reduce renal tubular damage caused by AKI, improve renal tubular epithelial cell apoptosis and inflammation, and promote renal cell function repair.

The application provides a kind of diabetes nephropathy auxiliary identification method and system based on CT image, it is related to medical image processing and computer-aided diagnosis technical field, the method comprises: obtaining the abdominal CT image of target object;Segment kidney, perirenal fat and body composition region of interest;Extract radiomics features;Screening to obtain target radiomics features;Input radiomics model to obtain whether target object is identified result of suffering from diabetes nephropathy.The application extracts microcosmic image markers related to renal function damage from conventional CT images by comprehensively using multiple site radiomics features, realizes non-invasive, accurate auxiliary identification of diabetes nephropathy, significantly improves detection efficiency, and provides a reliable image-aided diagnosis tool for clinic.

The invention provides application of Qixuekang in preparation of a medicine for treating renal fibrosis. Experimental research proves that the Qixuekang administration can remarkably recover the renal function of a mouse with renal fibrosis in senescence-accompanied chronic kidney diseases, reduce the mouse kidney mesenchymal fibrosis level and the levels of fibrosis markers alpha-SMA and Col1, recover the content of reductive glutathione in the mouse, improve the activity of superoxide dismutase and improve the curative effect of the kidney fibrosis in the senescence-accompanied chronic kidney diseases. Therefore, kidney fibrosis phenotypes and fibrosis-related biochemical indexes of mice are improved. Qi-blood Kang can remarkably restore kidney mesenchymal transformation related gene and protein expression, and kidney fibrosis phenotypes in chronic kidney diseases are improved by reducing related inflammatory media; qiwankang can significantly improve mitochondrial membrane potential, increase mitochondrial neogenesis related gene expression and reduce generation of active oxygen.

The present invention provides a method for improving renal function, and a compound for regulating the expression and function of CUBN and can be used in the method for improving renal function.　Renal function was successfully improved using a CUBN inhibitor.

This invention discloses the application of a peptide SRD in the preparation of drugs for treating acute kidney injury, belonging to the field of biomedical technology. In an in vitro H2O2-induced oxidative stress injury experiment on renal tubular epithelial cells, this invention found that peptide SRD treatment significantly reduced the apoptosis rate of renal tubular cells damaged by oxidative stress, promoted ATP production, and restored mitochondrial respiratory chain function. In an animal model of ischemia-reperfusion-induced acute kidney injury, mice with acute kidney injury injected via the tail vein showed significantly decreased serum creatinine and blood urea nitrogen levels. Pathological observation revealed a significant reduction in the degree of renal tubular injury, a lower histological score, and a significant downregulation of KIM-1, an indicator of the degree of renal tubular injury. This indicates that the antioxidant peptide SRD can improve mitochondrial function in renal tubular cells, effectively reduce renal tubular cell damage, promote the repair of renal tubular epithelial cells in acute kidney injury (AKI), effectively improve renal function, and has a good therapeutic effect on acute kidney injury.

This invention relates to the field of pharmaceuticals, and more particularly to the application of honeysuckle glycosides or verbenacin in alleviating and / or delaying renal fibrosis. This invention has discovered that honeysuckle glycosides can significantly inhibit epithelial-mesenchymal transition, thereby protecting renal function. More unexpectedly, it has been found that the combined use of honeysuckle glycosides and verbenacin significantly enhances the anti-fibrotic effect compared to using either alone, exhibiting a synergistic effect without the serious drawbacks of commonly used clinical drugs. While verbenacin itself possesses certain anti-inflammatory and antioxidant activity, under the experimental conditions of this invention, the anti-fibrotic effect of verbenacin alone is weaker than that of honeysuckle glycosides; however, when used in combination with honeysuckle glycosides, the latter's anti-fibrotic effect is significantly enhanced, suggesting a complementary or synergistic molecular mechanism between the two. Therefore, honeysuckle glycosides, used alone or in combination with verbenacin, has a potent and low-toxicity therapeutic effect on renal fibrosis. Furthermore, both honeysuckle glycosides and verbenacin are natural compounds, low in toxicity, and readily accepted by the human body.

This invention belongs to the pharmaceutical field, specifically relating to a compound pharmaceutical preparation for treating chronic uric acid nephropathy and its application. This invention provides a compound pharmaceutical preparation for treating chronic uric acid nephropathy, which is a tablet composed of levocarnitine and trimetazidine in a certain proportion. The levocarnitine and trimetazidine compound preparation can significantly improve renal function in patients with chronic uric acid nephropathy and protect against kidney damage.